ESR1 and cancer: TNBCs were 33% less likely to be screen‐detected (OR = 0.67 95% CI 0.50–0.88) and more than two times more likely to be interval cancers than ER/PR+HER2− cancers (OR = 2.26 95% CI 1.60–3.20).